Oronsky B - Search Results

1

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR. Reid T, et al. Among authors: oronsky b, oronsky a. Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19. Lancet Oncol. 2015. PMID: 26296952 Clinical Trial.

2

Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Oronsky BT, Knox SJ, Scicinski J. Oronsky BT, et al. Transl Oncol. 2011 Aug;4(4):189-98. doi: 10.1593/tlo.11166. Epub 2011 Aug 1. Transl Oncol. 2011. PMID: 21804913 Free PMC article.

3

Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review.

Oronsky BT, Knox SJ, Scicinski JJ. Oronsky BT, et al. Transl Oncol. 2012 Apr;5(2):66-71. doi: 10.1593/tlo.11307. Epub 2012 Apr 1. Transl Oncol. 2012. PMID: 22496921 Free PMC article.

4

Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials.

Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Ning S, et al. Among authors: oronsky b. Cancer Res. 2012 May 15;72(10):2600-8. doi: 10.1158/0008-5472.CAN-11-2303. Cancer Res. 2012. PMID: 22589277

5

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.

Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL. Scicinski J, et al. Among authors: oronsky b. Drug Metab Dispos. 2012 Sep;40(9):1810-6. doi: 10.1124/dmd.112.046755. Epub 2012 Jun 14. Drug Metab Dispos. 2012. PMID: 22699395

6

Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

Oronsky BT, Scicinski JJ, Reid T, Knox S. Oronsky BT, et al. Transl Oncol. 2012 Jun;5(3):133-40. doi: 10.1593/tlo.12118. Epub 2012 Jun 1. Transl Oncol. 2012. PMID: 22741032 Free PMC article.

7

The scarlet letter of alkylation: a mini review of selective alkylating agents.

Oronsky BT, Reid T, Knox SJ, Scicinski JJ. Oronsky BT, et al. Transl Oncol. 2012 Aug;5(4):226-9. doi: 10.1593/tlo.12187. Epub 2012 Aug 1. Transl Oncol. 2012. PMID: 22937173 Free PMC article.

8

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J. Paulmurugan R, et al. Among authors: oronsky b. Theranostics. 2013 May 25;3(6):437-47. doi: 10.7150/thno.5658. Print 2013. Theranostics. 2013. PMID: 23781290 Free PMC article. Review.

9

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients.

Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J. Reid T, et al. Among authors: oronsky b. Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382. eCollection 2014 Jan. Case Rep Oncol. 2014. PMID: 24575021 Free PMC article.

10

The implications of hyponitroxia in cancer.

Oronsky B, Fanger GR, Oronsky N, Knox S, Scicinski J. Oronsky B, et al. Among authors: oronsky n. Transl Oncol. 2014 Apr;7(2):167-73. doi: 10.1016/j.tranon.2014.02.001. Epub 2014 Mar 4. Transl Oncol. 2014. PMID: 24731473 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page